More than just a vial...
New technologies allow scientists to measure thousands of proteins
from a vial of blood.
...powerful health insights
Proteins Express Health
More than just a vial...
New technologies allow scientists to measure thousands of proteins
from a vial of blood.
...powerful health insights
We leverage health prediction algorithms across healthcare ecosystem
Howard W. Sams
Chief Executive Officer
Previously Global Head of Siemens Digital and Computational Pathology business. Global leadership roles in Roche Diagnostics over a decade. Multiple roles at Guidant/Boston Scientific, started career at Conseco. BS, Butler University & MBA from the University of Notre Dame.
Leena Das-Young, PharmD
SVP, Strategy & Innovations
Led early cancer detection at Guardant Health. Prior Global Head of Pfizer Late Phase Oncology development with multiple leadership roles in commercial & development at Pfizer & Bayer. Pre-industry roles in AIDS clinical research & direct patient care in various health systems. BS & PharmD from Purdue University.
David Perlman, Ph.D.
VP, Head of Proteomics
More than 25 years at the cutting-edge of the Proteomics field. Directed the Ultrasensitive & Single-cell Proteomics biomarker and drug discovery group at Merck. Previously, Head of Target Discovery at Crescenta Biosciences and Director of the Collaborative Proteomics Center at Princeton University. Ph.D. and Post-docs in Cell & Molecular Biology, Virology and Proteomics, BU School of Medicine.
Nicola Jessen
Head of Marketing
Leads our Marketing efforts. Previously Head of Company Digitalization & Automation at Siemens Healthineers for Central Eastern Europe and Central Asia. Multiple global roles in strategy, M&A, digital transformation, change management, and product development. Several years of experience as Head of Marketing at a German startup.
Sharon Reece
Head of Accounting
Leads the Accounting and financial reporting for Health Outlook. CFO Partner at TechCXO with extensive experience in life sciences. Previously Chief Financial Officer and Vice President of Finance & Compliance at AgNovos Bioscience, BioReliance, and United BioSource Corporation. B.S. in Accounting, Penn State University and Certified Public Accountant.
Travis Read
Head of Business Development
Leads all deal related activities and externalization efforts for the Company. Previous roles include senior positions in private equity and private equity backed biopharmaceutical companies including Gurnet Point Capital, Coherus Biosciences and M8 Pharmaceuticals. B.A., University of California, Berkeley.
Tim Opler, Ph.D.
Co-Founder
Partner at Torreya, former professor and entrepreneur. Serves on boards of multiple private companies. Previously at Credit Suisse in healthcare investment banking and at FibroGen in a strategy role. Ph.D., Econ, UCLA.
Jeremy Bowser
SVP, Operations
Leads our Operations division. Previously led implementation, contracting and commercial education Teams at Roche Diagnostics. Retired Navy SEAL with 25 years of global experience in executive leadership, mentorship, and advisory roles. Decorated combat veteran. BS, University of Charleston and is an MBA candidate with University of Chicago Booth School of Business.
Jason Wang
Chief Medical Scientist
Director of the Center for Policy, Outcomes, and Prevention, and Professor of Pediatrics and Health Policy at Stanford University. Co-chairs the mobile health and other new technologies group at the Stanford Center for Population Health Sciences. B.S. in molecular biology from MIT, M.D. from Harvard Medical School, and Ph.D. in policy analysis from RAND.
Lisa Uthgenannt
Head of Human Resources
Seasoned global HR executive with extensive experience in healthcare services, medical devices, pharmaceuticals and chemicals industries. Most recently delivered consulting services to start-up companies. Previously Chief Human Resources Officer at LabCorp and Senior Vice Present of Human Resources at Covance and Johnson & Johnson.
Joseph Konowiecki, J.D.
Chairman,
Alignment Health
As General Counsel for PacifiCare, one of the nation's largest health organizations, he was instrumental in closing its $9.2 billion sale to United Health. He is currently Chairman of Alignment Healthcare, a rapidly growing Medicare insurer. He serves on the board of directors for Health Outlook.
Tadd Wessel
Managing Partner, Petrichor Healthcare Capital Management
Mr. Wessel was formerly a Managing Director at OrbiMed Advisors and Vice President at Fortress Investment Group. He sits on numerous boards of directors of life sciences companies as well as the International Centers for Precision Oncology (ICPO) Foundation. A.B. in Biology from Princeton University.
Adam Morgan
Partner at Avego,
CIO of Velan Capital
Career spanning two decades through the healthcare and fundamental asset management. Before Avego he worked at Broadfin Capital, Iguana Healthcare and Pura Vida Investments. Previous role at Cowen and Company. BS in Chemistry from the University of Minnesota, MBA from the Carlson School of Management at the University of Minnesota.
Peter Koerte, Ph.D.
Chief Technology & Strategy Officer, Siemens
As CTO and CSO for Siemens AG, Peter is responsible for strategy, digitization and establishment of the industrial internet of things (IoT). Peter has had multiple global management roles at Siemen Healthineers and has also worked at BCG. He received a Ph.D. in strategy and international management from WHU Otto Beisheim School of Management.
Howard W. Sams
Chief Executive Officer,
Health Outlook
Previously Global Head of Siemens Digital and Computational Pathology business. Global leadership roles in Roche Diagnostics over a decade. Multiple roles at Guidant/Boston Scientific, started career at Conseco. BS, Butler University & MBA from the University of Notre Dame.
Tim Opler, Ph.D.
Co-Founder,
Health Outlook
Partner at Torreya, former professor and entrepreneur. Serves on boards of multiple private companies. Previously at Credit Suisse in healthcare investment banking and at FibroGen in a strategy role. Ph.D., Econ, UCLA.
John Rydzewski
Co-Founder,
Health Outlook
Private investor, advisor and director to healthcare companies and health policy organizations following investment banking and asset management careers. Chairman, RAND Health Board of Advisors and a member of the University of Pennsylvania School of Nursing Board of Advisors. MBA and BS from The Wharton School.
Andy Dannenberg, M.D.
Former Professor Medicine,
Weill Cornell Medical College
Partner at Emerald Bioventures. Formerly was Professor of Medicine at Weill Cornell Medical College. Author of 200+ scientific publications. Expert on inflammation and cancer. MD Wash U., St. Louis.
Richard Ulevitch, Ph.D.
Dept. Immunology,
Scripps Research Institute
Richard Ulevitch is professor of immunology and Chairman Emeritus of the Department of Immunology at The Scripps Research Institute. His career is marked by a number of seminal scientific discoveries in the field of innate immunity. He has a strong ongoing interest in implications of proteomics for science and medicine. He received a Ph.D. in Immunology from the University of Pennsylvania.
Paul Ridker, M.D.
Professor of Medicine,
Harvard University
Dr. Ridker is a cardiovascular epidemiologist and biomedical researcher whose research has provided proof-of-principle for the inflammation hypothesis of atherosclerosis and the first proven anti-inflammatory treatment for coronary artery disease.
David Shulkin, M.D.
Former Secretary,
Veterans Administration
Dr. Shulkin is an American physician and former U.S. Secretary of Veterans Affairs. Shulkin was also CEO of Beth Israel Medical Center and was president of Morristown Medical Center. He was the first CMO of the University of Pennsylvania Hospital.
Thomas E. Rohan, M.B.B.S., PH.D., D.H.Sc.
Professor, Department of Epidemiology & Population Health
Dr. Rohan is a cancer epidemiologist who studies the role of genetic/molecular, nutritional, and hormonal factors in the etiology and pathogenesis of a wide range of cancers. In addition to being chair of the department of epidemiology and population health, Dr. Rohan is associate director for population sciences in the Albert Einstein Cancer Center. He is on the editorial board of several journals, and is a member of several professional societies.
Mark Simon
Co-Founder and Advisor,
Torreya
Mark Simon is a partner at Torreya Partners, which he co-founded in 2007. He brings over 20 years of experience in advising biotech companies. He is active on numerous boards including that for the Alliance for Aging Research. Before Torreya, Simon in investment banking at Citigroup and Robertson Stephens. Mark received an MBA from Harvard Business School.
Dan Lewis
Lobesity
Board Member
Accomplished C-suite executive across multiple industries. Recently, worked in healthcare as the COO of a $1.5B hospital system and in biotech as the CEO of Lobesity, a start-up company dedicated to the treatment of obesity. Successfully led the exit in 2021 and remains a Board Member. Currently, advises other start-ups in the health tech sector. Received a BA degree from Kent State University and an MA from the University of Akron.
The Health
Prediction Company